Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 566 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol administration; Placebo administration Clear all
Completed Phase 2 Interventional Results available

Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.

NCT02185131
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Mirtazapine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 3 Interventional

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain

NCT00643383
View directory record Official record
Conditions
Acute Low Back Pain
Interventions
Combination drug (Acetaminophen + Tramadol), Placebo
Drug
Lead sponsor
Labopharm Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Montgomery, Alabama • Centennial, Colorado • Hialeah, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 3 Interventional

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00685841
View directory record Official record
Conditions
COPD
Interventions
Arformoterol tartrate inhalation solution, Salmeterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
52
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

NCT01861457
View directory record Official record
Conditions
Infectious Disease
Interventions
Nozin® Nasal Sanitizer®, Placebo
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 1 Interventional

Development of Ibudilast for Alcohol Use Disorder

NCT02025998
View directory record Official record
Conditions
Alcohol Use Disorders
Interventions
Ibudilast, Matched placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

NCT00746330
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
Drug
Lead sponsor
Novartis
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol Self Administration Laboratory

NCT00398918
View directory record Official record
Conditions
Alcoholism
Interventions
zonisamide, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Not applicable Interventional Results available

The Effect of Salmeterol on Eosinophil (EOS) Function

NCT00214019
View directory record Official record
Conditions
Allergic Asthma
Interventions
salmeterol, Fluticasone, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Body Composition Changes With Albuterol and Caffeine Versus Placebo in Adolescents

NCT02740660
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Caffeine 100mg / Albuterol 4mg, Placebo, Family weight management counseling
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 3 Interventional

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1

NCT00218660
View directory record Official record
Conditions
Alcoholism, Cocaine Dependence
Interventions
Naltrexone, BRENDA, CBT, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo
Drug
Lead sponsor
Kindeva Drug Delivery
Industry
Eligibility
18 Years and older
Enrollment
1,762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

NCT06067828
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Tarzana, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

NCT01218100
View directory record Official record
Conditions
Stage 2 Diastolic Hypertension
Interventions
nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
89
States / cities
Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

NCT01641692
View directory record Official record
Conditions
Asthma
Interventions
GSK573719 Active treatment or Placebo, GSK573719 (Sub-group cohort), Salbutamol/Albuterol
Drug · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Newport Beach, California • Sunset, Louisiana • Bethesda, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 23, 2026, 9:06 PM EDT
Terminated Phase 2 Interventional Results available

Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

NCT00862563
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Alcohol Abuse
Interventions
Topiramate, Zonisamide, Levetiracetam, Sugar Pill
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 23, 2026, 9:06 PM EDT
Terminated Phase 2 Interventional Results available

Vigabatrin for Cocaine and Alcohol Dependence

NCT01335867
View directory record Official record
Conditions
Alcoholism, Cocaine Dependence
Interventions
Vigabatrin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Study of the Medication Prazosin for Alcohol Dependence

NCT00762710
View directory record Official record
Conditions
Alcoholism
Interventions
Prazosin medication, Placebo medication
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol as a Treatment for AUD Comorbid With PTSD

NCT03248167
View directory record Official record
Conditions
Alcohol Use Disorder, Post Traumatic Stress Disorder
Interventions
Cannabidiol, Placebos
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075
View directory record Official record
Conditions
Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions
Siemens 3T PRISMA MR Scanner, PET/CT Scanner, Suvorexant, Placebo
Device · Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

NCT02177175
View directory record Official record
Conditions
Breast Cancer
Interventions
Carvedilol, placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 23, 2026, 9:06 PM EDT
Completed Phase 2 Interventional

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00691405
View directory record Official record
Conditions
COPD
Interventions
Arformoterol tartrate inhalation solution, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
31
States / cities
Encinitas, California • Long Beach, California • Brandon, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Phase 3 Interventional

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

NCT05432466
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
ACER-002 (celiprolol) 200 mg BID, Placebo BID
Drug
Lead sponsor
Acer Therapeutics Inc.
Industry
Eligibility
15 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

HA35 Acute Alcohol Study

NCT05025865
View directory record Official record
Conditions
Healthy Controls
Interventions
Sodium Hyaluronate, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 9:06 PM EDT